Patents Assigned to Bellicum Pharmaceuticals, Inc.
-
Patent number: 11839647Abstract: The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide. The technology further relates in part to methods for inducing partial apoptosis of cells that express an inducible modified caspase polypeptide, having a modified dose response curve to the multimeric ligand inducer. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide or the inducible modified caspase polypeptide, where the proportion of caspase polypeptide-expressing cells eliminated by apoptosis is related to the administered amount of the multimeric ligand inducer.Type: GrantFiled: January 3, 2020Date of Patent: December 12, 2023Assignee: Bellicum Pharmaceuticals, Inc.Inventors: Kevin Slawin, David Michael Spencer, Aaron Edward Foster
-
Patent number: 10934346Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides. The technology further relates in part to therapeutic methods for inducing an immune response and treating tumors in a patient.Type: GrantFiled: February 13, 2015Date of Patent: March 2, 2021Assignee: Bellicum Pharmaceuticals, Inc.Inventors: Aaron Edward Foster, David Spencer, Matthew Robert Collinson-Pautz, Kevin Slawin
-
Patent number: 10888608Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.Type: GrantFiled: September 1, 2015Date of Patent: January 12, 2021Assignee: Bellicum Pharmaceuticals, Inc.Inventors: David Spencer, Aaron Edward Foster, Kevin Slawin
-
Patent number: 10525110Abstract: The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide. The technology further relates in part to methods for inducing partial apoptosis of cells that express an inducible modified caspase polypeptide, having a modified dose response curve to the multimeric ligand inducer. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide or the inducible modified caspase polypeptide, where the proportion of caspase polypeptide-expressing cells eliminated by apoptosis is related to the administered amount of the multimeric ligand inducer.Type: GrantFiled: February 5, 2018Date of Patent: January 7, 2020Assignee: Bellicum Pharmaceuticals, Inc.Inventors: Kevin Slawin, David Spencer, Aaron Edward Foster
-
Patent number: 9944690Abstract: The technology relates generally to the field of immunology and relates in part to compositions and methods for controlling the proliferation of T cells, for example, therapeutic T cells. The methods further relate to compositions and methods for inducing an immune response in a subject.Type: GrantFiled: March 13, 2014Date of Patent: April 17, 2018Assignee: BELLICUM PHARMACEUTICALS, INC.Inventors: David Spencer, Aaron Edward Foster, Kevin Slawin
-
Patent number: 9932572Abstract: The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.Type: GrantFiled: July 29, 2016Date of Patent: April 3, 2018Assignee: Bellicum Pharmaceuticals, Inc.Inventors: David Spencer, Wei-Chun Chang
-
Patent number: 9913882Abstract: The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide. The technology further relates in part to methods for inducing partial apoptosis of cells that express an inducible modified caspase polypeptide, having a modified dose response curve to the multimeric ligand inducer. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide or the inducible modified caspase polypeptide, where the proportion of caspase polypeptide-expressing cells eliminated by apoptosis is related to the administered amount of the multimeric ligand inducer.Type: GrantFiled: June 4, 2014Date of Patent: March 13, 2018Assignee: Bellicum Pharmaceuticals, Inc.Inventors: Kevin Slawin, David Spencer, Aaron Edward Foster
-
Patent number: 9434935Abstract: The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.Type: GrantFiled: March 10, 2013Date of Patent: September 6, 2016Assignee: BELLICUM PHARMACEUTICALS, INC.Inventors: David Spencer, Wei-Chun Chang
-
Publication number: 20150111294Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.Type: ApplicationFiled: March 5, 2013Publication date: April 23, 2015Applicant: BELLICUM PHARMACEUTICALS, INC.Inventor: BELLICUM PHARMACEUTICALS, INC.
-
Publication number: 20140286987Abstract: The technology relates generally to the field of immunology and relates in part to compositions and methods for controlling the proliferation of T cells, for example, therapeutic T cells. The methods further relate to compositions and methods for inducing an immune response in a subject.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicant: BELLICUM PHARMACEUTICALS, INC.Inventors: David SPENCER, Aaron Edward Foster
-
Publication number: 20140087468Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.Type: ApplicationFiled: February 8, 2013Publication date: March 27, 2014Applicant: BELLICUM PHARMACEUTICALS, INC.Inventor: BELLICUM PHARMACEUTICALS, INC.
-
Publication number: 20140023647Abstract: Provided herein are methods for treating a solid tumor in a subject in need thereof by activating an immune response against a tumor antigen. Also provided are methods for treating a solid tumor in a subject in need thereof by activating antigen-presenting cells and eliciting an immune response against a tumor antigen. Also provided herein are optimized therapeutic treatments of solid tumors, which comprise determining the presence, absence or amount of a biomarker after the therapy has been administered, and determining whether a subsequent dose of the therapy should be maintained, increased, or decreased based on the biomarker assessment.Type: ApplicationFiled: March 6, 2013Publication date: January 23, 2014Applicant: BELLICUM PHARMACEUTICALS, INC.Inventors: Kevin SLAWIN, David Spencer, Natalia Lapteva
-
Publication number: 20130323834Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.Type: ApplicationFiled: March 6, 2013Publication date: December 5, 2013Applicant: BELLICUM PHARMACEUTICALS, INC.Inventor: BELLICUM PHARMACEUTICALS, INC.
-
Publication number: 20130183333Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.Type: ApplicationFiled: March 5, 2013Publication date: July 18, 2013Applicant: BELLICUM PHARMACEUTICALS, INC.Inventor: BELLICUM PHARMACEUTICALS, INC.
-
Patent number: 8486693Abstract: Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.Type: GrantFiled: September 19, 2012Date of Patent: July 16, 2013Assignee: Bellicum Pharmaceuticals, Inc.Inventors: Dongsu Park, David Spencer, Natalia Lapteva